Nordion Completes Divestiture of Targeted Therapies Business to BTG plc

OTTAWA, Ontario–(BUSINESS WIRE)–Jul. 15, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced that it has completed the divestiture of its Targeted Therapies business to BTG plc (LSE: BTG), an international specialist healthcare company based in London, United Kingdom for a cash purchase price of US$200 million. Nordion intends to provide an update in respect to its use of net transaction proceeds within the next 60 days.
About Nordion
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes and sterilization technologies that benefit the lives of millions of people in more than 40 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 450 highly skilled employees in three locations. Find out more at and follow us at
Forward-Looking Statements
This news release contains “forward-looking statements” relating to an intended update regarding the use of the net transaction proceeds that are not historical facts. Such statements are subject to known and unknown important risks, uncertainties, assumptions and other factors that may cause actual results or events to differ materially from the forward-looking statements in this news release.
The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. Except as may be required by securities laws, we do not undertake any obligation to update or revise any forward-looking statements contained in this news release, whether as a result of new information, future events or otherwise. Additionally, we undertake no obligation to comment on expectations of, or statements made by, third parties in respect of the intended update regarding the use of the net transaction proceeds.
For additional information with respect to certain of these and other beliefs, assumptions, risks and uncertainties, please refer to Nordion’s Annual Information Form for fiscal 2012 available on SEDAR at and on EDGAR on These documents are also available on Nordion’s website at
Source: Nordion Inc.
Nordion Inc.
Ana Raman, (613) 595-4580
[email protected]
Shelley Maclean, (613) 592-3400 x. 2414
[email protected]